Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
Ocugen (NASDAQ: OCGN) said it signed a binding term sheet to negotiate an exclusive license for its OCU400 modifier gene therapy for retinitis pigmentosa in the Middle East and North Africa with Roots Pharmaceutical and Al-Dhow International Holding. Ocugen expects up to $4 million in upfront and near-term milestones, up to $255 million in sales milestones, and 22% royalties on net sales. Ocugen will manufacture OCU400, with a definitive deal expected within 90 days.
How this was made
The 30-second read
Why it matters
The disclosed term sheet adds concrete financial terms (up to $4M upfront/near-term milestones, up to $255M sales milestones, and 22% royalties) and assigns Ocugen manufacturing and supply responsibilities, which can improve near-to-mid-term expectations for OCU400’s commercialization in MENA.
Market read
Traders may reprice OCGN on the combination of disclosed deal economics and the stated path to definitive agreements, while monitoring execution risk and Phase 3 milestones.
What to watch
The article does not specify regulatory strategy, reimbursement expectations, or manufacturing capacity constraints for MENA; these could materially affect the probability of reaching sales milestones.
Background
Ocugen is advancing OCU400, a modifier gene therapy for retinitis pigmentosa, through Phase 3 liMeliGhT with a topline readout expected in 1Q 2027.
Ticker impact
Ocugen signed a binding term sheet to license OCU400 for exclusive MENA rights, with up to $4M upfront/near-term milestones and up to $255M sales milestones plus 22% royalties.
Likely positive bias for OCGN, with magnitude dependent on market confidence in definitive agreement timing and Phase 3 progress.
This is a primary disclosure of binding term sheet economics (upfront, milestones, royalties) and a stated path to definitive agreement within 90 days, but it is not yet the final license agreement and clinical timelines remain forward-looking.
Market effects
Reinforces ongoing investor appetite for gene-therapy commercialization partnerships tied to milestone and royalty structures.
Highlights MENA as a targeted geography for inherited retinal disease therapies, potentially increasing attention to regional distribution partners.
Supports the broader gene-therapy licensing model where regional partners fund commercialization while innovators retain royalties and manufacturing roles.
Counterpoint
Because this is only a binding term sheet, the market may discount the economics until the definitive license and supply agreements are executed and operational details are confirmed.
Key entities
- public_companyOcugen, Inc.
NASDAQ-listed gene therapy company announcing the binding term sheet for OCU400 licensing in MENA.
- companyRoots Pharmaceutical
Partner expected to obtain exclusive MENA rights for OCU400 under a definitive license agreement.
- companyAl-Dhow International Holding
Strategic partner associated with Roots Pharmaceutical in the MENA licensing arrangement.
- productOCU400
Ocugen’s modifier gene therapy for retinitis pigmentosa covered by the proposed license and supply agreements.
